Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | EIF4E | P06730 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180259 | 0.82 | HTR2B (0.50) | HTR2BBCAT2EIF4EACHENPC1 | |
| SCHEMBL3260631 | 0.81 | CHRM1 (0.52) | HTR2BBCAT2EIF4EACHENPC1 | |
| SCHEMBL2706854 | 0.81 | TGFBR1 (0.51) | HTR2BBCAT2EIF4EACHENPC1 | |
| SCHEMBL2227207 | 0.78 | HTR2B (0.47) | HTR2BBCAT2EIF4EACHENPC1 | |
| SCHEMBL5968562 | 0.78 | RAB9A (0.62) | BCAT2EIF4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1968034 | 0.77 | HTR2B (0.46) | HTR2BBCAT2EIF4EACHENPC1 | |
| SCHEMBL30263359 | 0.77 | EIF4E (0.46) | HTR2BEIF4EACHEKDM4EALDH1A1 | |
| SCHEMBL11177459 | 0.76 | HTR2B (0.44) | HTR2BBCAT2EIF4EACHENPC1 | |
| SCHEMBL30263366 | 0.76 | KDM4E (0.45) | EIF4ENPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30263367 | 0.75 | CYP19A1 (0.57) | BCAT2EIF4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179711-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | US | disclosed |
| US-8680103-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1711481-B2 | CRYSTALLINE MONOHYDRATE AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| US-8242270-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-14 | — | — | US | disclosed |
| US-7652146-B2 | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1711481-B1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090149650-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-11 | — | — | US | disclosed |
| US-7491725-B2 | purification of crystalline N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (IV) using ethanol/water mixture; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1711481-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20060004067-A1 | N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition; anticancer, psoriasis | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050215795-A1 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | disclosed |
| WO-2005077945-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005076990-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-CARBOXAMIDES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176965-A1 | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | HTR2B 948/4885BCAT2 329/4885EIF4E 712/4885 |
| US-20060004067-A1 | N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition; anticancer, psoriasis | TYK2, BRAF, ERBB2 | HTR2B 1641/4885BCAT2 857/4885EIF4E 791/4885 |
| US-20090149650-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | HTR2B 948/4885BCAT2 329/4885EIF4E 712/4885 |
| US-20050215795-A1 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | MAP3K5, MAP3K2, MAP3K20 | HTR2B 948/4885BCAT2 329/4885EIF4E 712/4885 |
| US-20050176965-A1 | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors | CDK2, MAP3K5, MAP4K2 | HTR2B 1254/4885BCAT2 499/4885EIF4E 568/4885 |
| US-20140179711-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | HTR2B 948/4885BCAT2 329/4885EIF4E 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.